- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
568
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
568 companies
Longeveron
Market Cap: US$16.7m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.79
7D
-4.4%
1Y
-61.7%
EyePoint Pharmaceuticals
Market Cap: US$965.7m
Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
EYPT
US$14.01
7D
21.1%
1Y
70.0%
AN2 Therapeutics
Market Cap: US$34.4m
A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
ANTX
US$1.26
7D
14.5%
1Y
21.2%
ArriVent BioPharma
Market Cap: US$819.1m
A clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
AVBP
US$20.19
7D
5.6%
1Y
-27.2%
Grace Therapeutics
Market Cap: US$44.3m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$3.20
7D
5.6%
1Y
30.6%
Chemomab Therapeutics
Market Cap: US$16.0m
A clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
CMMB
US$3.09
7D
-1.6%
1Y
-63.7%
Catalyst Pharmaceuticals
Market Cap: US$2.5b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$20.29
7D
-1.5%
1Y
3.3%
C4 Therapeutics
Market Cap: US$193.6m
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
CCCC
US$2.72
7D
4.6%
1Y
-52.5%
ImmuCell
Market Cap: US$57.3m
An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
ICCC
US$6.33
7D
-1.1%
1Y
63.6%
CareDx
Market Cap: US$735.6m
Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
CDNA
US$13.82
7D
1.2%
1Y
-49.6%
Atea Pharmaceuticals
Market Cap: US$267.4m
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
AVIR
US$3.37
7D
0.3%
1Y
-8.2%
Kiora Pharmaceuticals
Market Cap: US$9.2m
A clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
KPRX
US$2.68
7D
-3.6%
1Y
-22.5%
Universe Pharmaceuticals
Market Cap: US$2.0m
Through its subsidiaries, engages in the manufacturing, marketing, distribution, and sells of traditional Chinese medicine derivative products in China.
UPC
US$3.55
7D
0.1%
1Y
-99.8%
Dynavax Technologies
Market Cap: US$1.2b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$10.06
7D
-0.6%
1Y
-7.5%
Climb Bio
Market Cap: US$162.0m
A clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.
CLYM
US$2.39
7D
7.2%
1Y
-69.5%
Enzon Pharmaceuticals
Market Cap: US$6.7m
Does not have significant operations.
ENZN
US$0.09
7D
-0.2%
1Y
-35.9%
Clearmind Medicine
Market Cap: US$5.3m
A clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems.
CMND
US$1.03
7D
-2.4%
1Y
-24.8%
Polyrizon
Market Cap: US$11.5m
A biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
PLRZ
US$1.02
7D
-6.4%
1Y
n/a
Nkarta
Market Cap: US$160.5m
A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
NKTX
US$2.26
7D
6.6%
1Y
-61.8%
Entera Bio
Market Cap: US$94.1m
A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs.
ENTX
US$2.06
7D
6.7%
1Y
10.2%
Theravance Biopharma
Market Cap: US$702.5m
A biopharmaceutical company, develops and commercializes of medicines in the United States.
TBPH
US$13.95
7D
0.5%
1Y
74.4%
Rapport Therapeutics
Market Cap: US$524.1m
Operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
RAPP
US$14.36
7D
-18.5%
1Y
-27.0%
Design Therapeutics
Market Cap: US$367.3m
A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
DSGN
US$6.45
7D
16.6%
1Y
32.3%
Corbus Pharmaceuticals Holdings
Market Cap: US$120.8m
A biopharmaceutical company, develops products to defeat serious illness.
CRBP
US$9.86
7D
5.2%
1Y
-81.3%
Anika Therapeutics
Market Cap: US$128.9m
A joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
ANIK
US$8.94
7D
-4.7%
1Y
-63.2%
Terns Pharmaceuticals
Market Cap: US$631.8m
A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.
TERN
US$7.22
7D
3.7%
1Y
-20.8%
Fate Therapeutics
Market Cap: US$116.5m
A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
FATE
US$1.01
7D
-2.9%
1Y
-70.7%
Eledon Pharmaceuticals
Market Cap: US$162.3m
Operates as a clinical stage biotechnology company.
ELDN
US$2.71
7D
4.6%
1Y
9.7%
Fulcrum Therapeutics
Market Cap: US$414.3m
A clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
FULC
US$7.66
7D
18.2%
1Y
-11.2%
Reflect Scientific
Market Cap: US$4.7m
Through its subsidiaries, engages in the design, development, and sale of scientific equipment for the life science and manufacturing industries worldwide.
RSCF
US$0.055
7D
-8.8%
1Y
-0.7%
Innoviva
Market Cap: US$1.3b
Engages in the development and commercialization of pharmaceutical products in the United States and internationally.
INVA
US$20.48
7D
0.2%
1Y
6.3%
Bicycle Therapeutics
Market Cap: US$496.2m
A clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
BCYC
US$7.16
7D
-3.0%
1Y
-72.8%
Black Diamond Therapeutics
Market Cap: US$167.4m
A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
BDTX
US$2.94
7D
6.9%
1Y
-48.1%
Neurocrine Biosciences
Market Cap: US$14.3b
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
NBIX
US$144.10
7D
3.2%
1Y
19.4%
Incyte
Market Cap: US$16.9b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$86.64
7D
2.4%
1Y
39.2%
Stoke Therapeutics
Market Cap: US$1.1b
An early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
STOK
US$20.68
7D
4.7%
1Y
34.7%